Compounds > phenylalanine

phenylalanine and Thrombocythemia

phenylalanine has been researched along with Thrombocythemia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dirnhofer, S; Duek, A; Grisouard, J; Hao-Shen, H; Kubovcakova, L; Shimizu, T; Skoda, RC1
Ziakas, PD1
Bay, JO; Berger, MG; Chaleteix, C; Fleury, J; Gouas, L; Goumy, C; Ledoux-Pilon, A; Richard-Pebrel, C; Tchirkov, A; Tournilhac, O; Vago, P; Véronèse, L1
Andrikovics, H; Csukly, Z; Halm, G; Király, V; Lovas, N; Lueff, S; Masszi, T; Mátrai, Z; Meggyesi, N; Mikala, G; Nahajevszky, S; Sipos, A; Szilvási, A; Tamáska, J; Tordai, A1
Steensma, DP; Tefferi, A1
Canellos, GP; DeVita, VT; Mason, JE1

Other Studies

6 other study(ies) available for phenylalanine and Thrombocythemia

ArticleYear
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
    Blood, 2015, Mar-26, Volume: 125, Issue:13

    Topics: Amino Acid Substitution; Animals; Bone Marrow; Bone Marrow Neoplasms; Disease Models, Animal; Disease Progression; Gene Deletion; Hematopoietic Stem Cells; Janus Kinase 2; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Phenylalanine; STAT3 Transcription Factor; Thrombocytosis; Valine

2015
Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.
    Haematologica, 2008, Volume: 93, Issue:9

    Topics: Humans; Janus Kinase 2; Phenylalanine; Risk Factors; Thrombocythemia, Essential; Thrombocytosis; Thrombosis; Uncertainty; Valine

2008
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Phenylalanine; Piperazines; Pyrimidines; Thrombocytosis; Valine

2010
[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Orvosi hetilap, 2007, Feb-04, Volume: 148, Issue:5

    Topics: Adult; Aged; Biopsy; Bone Marrow; Female; Gene Expression Regulation; Gene Frequency; Humans; Janus Kinase 2; Male; Middle Aged; Myeloproliferative Disorders; Phenotype; Phenylalanine; Point Mutation; Polycythemia Vera; Polymerase Chain Reaction; Primary Myelofibrosis; Thrombocytosis; Valine

2007
JAK2 V617F and ringed sideroblasts: not necessarily RARS-T.
    Blood, 2008, Feb-01, Volume: 111, Issue:3

    Topics: Anemia, Sideroblastic; Humans; Janus Kinase 2; Phenylalanine; Recurrence; Thrombocytosis; Valine

2008
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
    Blood, 1974, Volume: 44, Issue:4

    Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Transformation, Neoplastic; Humans; Hydroxyurea; Karyotyping; Leukemia, Myeloid; Mitolactol; Nitrogen Mustard Compounds; Phenylalanine; Primary Myelofibrosis; Prognosis; Splenomegaly; Thrombocytosis

1974